| April 2009 |
ADC collaboration with Millennium: The Takeda
Oncology Company |
| February 2009 |
Initiated pivotal trial of SGN-35 for Hodgkin
lymphoma |
| January 2009 |
Received Special Protocol Assessment (SPA)
from the FDA for pivotal trial of SGN-35 in Hodgkin lymphoma |
| July 2008 |
Initiated phase I clinical trial of SGN-70 |
| July 2008 |
ADC collaboration with Daiichi Sankyo |
| January 2008 |
Completed $103.5 million follow-on public
offering |
| November 2007 |
Initiated phase II clinical trial of
lintuzumab (SGN-33) |
| January 2007 |
Exclusive worldwide collaboration
agreement with Genentech for dacetuzumab (SGN-40) |
| January 2007 |
ADC co-development agreement with Agensys |
| December 2006 |
Initiated phase II clinical trial of
dacetuzumab (SGN-40) |
| November 2006 |
Initiated phase I clinical trial of SGN-35 |
| May 2006 |
Completed financings totaling $43 million |
| November 2005 |
Initiated phase I clinical trial of lintuzumab
(SGN-33) |
| June 2005 |
ADC collaboration with Progenics (PSMA Development Co.) |
| April 2005 |
ADC collaboration with MedImmune |
| April 2005 |
In-licensed anti-CD33 program from PDL
BioPharma |
| September 2004 |
ADC collaboration with Bayer Pharmaceuticals |
| July 2004 |
Co-development agreement with Celera Genomics |
| June 2004 |
ADC collaboration with CuraGen |
| March 2004 |
Initiated phase I clinical trial of
dacetuzumab (SGN-40) |
| February 2004 |
Completed $66 million follow-on public
offering |
| January 2004 |
Initiated phase II clinical trial of SGN-30 |
| December 2003 |
Expanded ADC collaboration with Genentech,
triggering receipt of a payment of $10 million |
| July 2003 |
Completed $41 million private placement |
| November 2002 |
Initiated phase I multi-dose clinical trial of
SGN-30 |
| April 2002 |
ADC collaboration with Genentech |
| March 2002 |
Initiated phase I single-dose clinical trial
of SGN-30 |
| June 2001 |
First ADC collaboration, with Eos
Biotechnology (acquired by PDL BioPharma) |
| March 2001 |
Completed initial public offering and
concurrent private placement raising a total of $51 million |
| February 2000 |
Completed in-licensing of cell-killing agent
Auristatin E from Arizona State University |
| December 1999 |
Completed $30 million Series B financing |
| September 1999 |
Completed in-licensing of anti-CD30 monoclonal
antibody from University of Miami, Florida |
| June 1998 |
Completed in-licensing of anti-CD40 monoclonal antibody from Mabtech
AB |
| April 1998 |
Completed $7 million Series A financing |
| March 1998 |
Completed
in-licensing agreement with Bristol-Myers Squibb covering extensive
intellectual property rights in the field of antibody-targeted therapy
for cancer |
| December 1997 |
First private financing completed |
| July 1997 |
Incorporated in the state of Delaware |